Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Hamblin

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pulmonary Medicine|June 11, 2011
Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemmaMark J Hamblin, Maureen R Horton
Cureus|June 4, 2020
Assessment of Optimal Screening Tests for the Detection of an Inflammatory Myositis-associated Interstitial Lung DiseaseSonia Castillo, Brietta Forbes, John Chen, et al.
The American Journal of Managed Care|May 18, 2021
The spectrum of progressive fibrosis interstitial lung disease: clinical and managed care considerationsMark J Hamblin, Robert J Kaner, Gary M Owens
Immunology and Allergy Clinics of North America|April 13, 2023
Hypersensitivity Pneumonitis: Updates in Evaluation, Management, and Ongoing DilemmasSahil M Pandya, Aarti P Pandya, Daffolyn Rachael Fels Elliott, et al.
International Journal of Biomedical Science : IJBS|October 18, 2014
Lovastatin Inhibits Low Molecular Weight Hyaluronan Induced Chemokine Expression via LFA-1 and Decreases Bleomycin-Induced Pulmonary FibrosisMark J Hamblin, Michael Eberlein, Katharine Black, et al.
Journal of Inflammation (London, England)|June 1, 2013
Hyaluronan fragments induce IFNβ via a novel TLR4-TRIF-TBK1-IRF3-dependent pathwayKatharine E Black, Samuel L Collins, Robert S Hagan, et al.
Respiratory Research|May 21, 2022
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension studyGanesh Raghu, Mark J Hamblin, A Whitney Brown, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
JAMA|May 26, 2018
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical TrialGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase IIb Randomized Clinical Study of an Anti-α<sub>v</sub>β<sub>6</sub> Monoclonal Antibody in Idiopathic Pulmonary FibrosisGanesh Raghu, Majd Mouded, Daniel C Chambers, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pulmonary Medicine|June 11, 2011
Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemmaMark J Hamblin, Maureen R Horton
Cureus|June 4, 2020
Assessment of Optimal Screening Tests for the Detection of an Inflammatory Myositis-associated Interstitial Lung DiseaseSonia Castillo, Brietta Forbes, John Chen, et al.
The American Journal of Managed Care|May 18, 2021
The spectrum of progressive fibrosis interstitial lung disease: clinical and managed care considerationsMark J Hamblin, Robert J Kaner, Gary M Owens
Immunology and Allergy Clinics of North America|April 13, 2023
Hypersensitivity Pneumonitis: Updates in Evaluation, Management, and Ongoing DilemmasSahil M Pandya, Aarti P Pandya, Daffolyn Rachael Fels Elliott, et al.
International Journal of Biomedical Science : IJBS|October 18, 2014
Lovastatin Inhibits Low Molecular Weight Hyaluronan Induced Chemokine Expression via LFA-1 and Decreases Bleomycin-Induced Pulmonary FibrosisMark J Hamblin, Michael Eberlein, Katharine Black, et al.
Journal of Inflammation (London, England)|June 1, 2013
Hyaluronan fragments induce IFNβ via a novel TLR4-TRIF-TBK1-IRF3-dependent pathwayKatharine E Black, Samuel L Collins, Robert S Hagan, et al.
Respiratory Research|May 21, 2022
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension studyGanesh Raghu, Mark J Hamblin, A Whitney Brown, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
JAMA|May 26, 2018
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical TrialGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase IIb Randomized Clinical Study of an Anti-α<sub>v</sub>β<sub>6</sub> Monoclonal Antibody in Idiopathic Pulmonary FibrosisGanesh Raghu, Majd Mouded, Daniel C Chambers, et al.
Pageof 2